
一种实验性细胞疗法在早期研究中显示出对抗晚期多发性骨髓瘤的迹象,包括在接受过类似治疗后癌症复发的患者中,这表明了一种克服强力疗法耐药性的新途径。
An experimental cell therapy showed signs of fighting advanced multiple myeloma, including in patients whose cancer had returned after receiving similar treatments, in an early-stage study that suggests a new way of overcoming resistance to the powerful therapies.
研究人员在《柳叶刀》上报告称,15名患者中有12名对这种名为TriPRIL的治疗产生了反应,其中8名实现了完全反应。这项首次人体研究在已接受中位数六线既往治疗的多发性骨髓瘤患者中测试了该疗法。
Twelve of 15 patients responded to the treatment, called TriPRIL, including eight who had complete responses, researchers reported in The Lancet. The first-in-human study tested the treatment in people with multiple myeloma who had already received a median of six previous lines of therapy.
该研究规模较小,主要旨在评估安全性,这意味着需要更大规模的试验来确定疗效及其持续时间。尽管如此,研究人员对该疗法在CAR-T细胞疗法后癌症已进展的患者中产生反应感到鼓舞。
The study is small and designed primarily to assess safety, meaning larger trials will be needed to establish how well the treatment works and how long its effects last. Still, researchers were encouraged that it produced responses in patients whose cancer had already progressed after CAR T-cell therapy.
CAR-T疗法通过收集患者自身的免疫细胞,对其进行基因重编程以识别和攻击癌细胞,然后再输回体内发挥作用。
CAR-T treatments work by collecting a patient’s own immune cells and genetically reprogramming them to recognize and attack cancer before returning them to the body.
这类疗法已改变了某些血液癌症的治疗格局,使部分患者获得长期缓解。然而在多发性骨髓瘤中,大多数患者最终会复发。原因之一是骨髓瘤细胞可进化以逃避工程免疫细胞的识别。
They have transformed treatment for some blood cancers, producing long-lasting remissions in some patients. In multiple myeloma, however, the cancer eventually returns in most patients. One reason is that myeloma cells can evolve to evade the engineered immune cells.
现有的多发性骨髓瘤CAR-T疗法旨在识别恶性浆细胞上一种名为BCMA的蛋白。TriPRIL由Mass General Brigham的研究人员设计,可同时识别BCMA和第二种名为TACI的蛋白,使改造后的免疫细胞在骨髓瘤细胞改变或丢失其中一种分子信号时,仍有另一种方式找到癌细胞。
Existing CAR-T treatments for multiple myeloma are designed to recognize a protein called BCMA found on malignant plasma cells. TriPRIL was engineered by researchers at Mass General Brigham to recognize BCMA and a second protein, called TACI, giving the modified immune cells another way of finding the cancer if myeloma cells change or lose one of those molecular signals.
“从传染病和癌症研究中我们学到的一点是,无论哪里有逃逸路径,肿瘤都会找到它,”Marcela Maus说。她负责Mass General Brigham癌症研究所的细胞免疫治疗项目,并领导了这项研究。“你是在通过靶向两个目标来堵住另一条出路。”在先前接受过类似CAR-T治疗的九名患者中,有六人产生了反应,其中五人实现了完全反应。根据该研究,其中一名患者在接受实验性治疗后22个月仍保持完全反应。
“One thing that we’ve learned from both infectious disease and cancer is that wherever there’s an escape route, the tumor will find it,” said Marcela Maus, who directs the cellular immunotherapy program at Mass General Brigham Cancer Institute and led the research. “You’re sort of blocking off another exit by targeting two things.”Among nine patients who had previously received a similar CAR-T treatment, six responded, including five who had complete responses. One remained in a complete response 22 months after receiving the experimental treatment, according to the study.
Maus警告说,这项小规模研究无法确定双靶点方法本身是否导致了这些反应。由于缺乏对照组,研究人员不知道部分患者是否也可能对仅靶向BCMA的另一种治疗产生反应。
Maus cautioned that the small study can’t establish whether the two-target approach itself was responsible for the responses. Without a comparison group, researchers don’t know whether some patients might also have responded to another treatment targeting BCMA alone.
这些发现尚属初步。患者的反应随访中位数仅为5.7个月,疾病恶化前的中位时间为5.8个月。患者数量少使得难以确定治疗效果的持久性。
The findings are preliminary. Patients had been followed for a median of only 5.7 months for response, and the median time before the disease worsened was 5.8 months. The small number of patients makes it difficult to determine how durable the treatment’s effects will be.
该治疗也产生了CAR-T疗法典型的副作用。13名患者出现了细胞因子释放综合征,这是一种由免疫激活引起的炎症反应,但无人出现严重病例。一名患者经历了中度神经毒性,且无治疗相关死亡病例。
The treatment also produced side effects typical of CAR-T therapy. Thirteen patients developed cytokine release syndrome, an inflammatory reaction caused by immune activation, although none had a severe case. One patient experienced moderate neurological toxicity, and there were no treatment-related deaths.
多发性骨髓瘤对大多数患者而言仍无法治愈,尽管较新的治疗手段意味着许多人现在能存活十年或更久。然而,癌症通常会复发,迫使患者在疾病变得日益难以控制时不断更换治疗方案。
Multiple myeloma remains incurable for most patients, although newer treatments mean many now survive a decade or longer. The cancer commonly returns, however, leaving patients to cycle through treatments as their disease becomes increasingly difficult to control.
Maus表示,需要一项涉及多家医院的更大规模研究,以确定这种实验性治疗是否能惠及更多患者。她创办了一家公司,协助开发用于治疗多发性骨髓瘤和其他疾病的TriPRIL。
A larger study involving multiple hospitals is needed to determine whether the experimental treatment can benefit more patients, Maus said. She founded a company to help develop TriPRIL for multiple myeloma and other diseases.